[
  {
    "ts": null,
    "headline": "Jim Cramer on Pfizer Inc. (PFE): ‘Still, Anything Good There, It Could Fly’",
    "summary": "We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the market following […]",
    "url": "https://finnhub.io/api/news?id=f96d93c8abb2274150dcb66abf115c6cc52a377d284a9e597839093466b6d8ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731970157,
      "headline": "Jim Cramer on Pfizer Inc. (PFE): ‘Still, Anything Good There, It Could Fly’",
      "id": 131463602,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other stocks Jim Cramer recently talked about. On Thursday, Jim Cramer, host of Mad Money, discussed the current state of the market following […]",
      "url": "https://finnhub.io/api/news?id=f96d93c8abb2274150dcb66abf115c6cc52a377d284a9e597839093466b6d8ca"
    }
  },
  {
    "ts": null,
    "headline": "RFK Jr.'s HHS nomination sparks concern over pharma stocks",
    "summary": "President-elect Trump’s decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical industry and GLP-1 drugs. Raymond James managing director and Washington Health Policy research analyst Chris Meekins joins Asking for a Trend Co-hosts Julie Hyman and Josh Lipton, sharing that Kennedy's lack of executive experience raises concerns about his ability to advance policy, including securing Medicare coverage. Despite these issues, Meekins suggests that the recent sell-off in pharmaceutical and GLP-1 stocks may be an overreaction. “The sell-off we've seen might be a little bit overdone compared to what the reality could end up at the end of the day,” Meekins said. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Cindy Mizaku.",
    "url": "https://finnhub.io/api/news?id=41009161802a53414fcbf11b745901181187d875107a5aeb86d60e51f4a49963",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731970142,
      "headline": "RFK Jr.'s HHS nomination sparks concern over pharma stocks",
      "id": 131461875,
      "image": "https://s.yimg.com/ny/api/res/1.2/DIGc_3owK5rhWF02H3BBYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/9364f230-a5fd-11ef-afce-2f223bdec554",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President-elect Trump’s decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical industry and GLP-1 drugs. Raymond James managing director and Washington Health Policy research analyst Chris Meekins joins Asking for a Trend Co-hosts Julie Hyman and Josh Lipton, sharing that Kennedy's lack of executive experience raises concerns about his ability to advance policy, including securing Medicare coverage. Despite these issues, Meekins suggests that the recent sell-off in pharmaceutical and GLP-1 stocks may be an overreaction. “The sell-off we've seen might be a little bit overdone compared to what the reality could end up at the end of the day,” Meekins said. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Cindy Mizaku.",
      "url": "https://finnhub.io/api/news?id=41009161802a53414fcbf11b745901181187d875107a5aeb86d60e51f4a49963"
    }
  },
  {
    "ts": null,
    "headline": "Top Analyst Reports for Thermo Fisher, NextEra Energy & Lowe's",
    "summary": "Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), NextEra Energy, Inc. (NEE) and Lowe's Companies, Inc. (LOW).",
    "url": "https://finnhub.io/api/news?id=c04205ec1ad75b076f0db65053f4ac6c5cb57ad200088e3c5ba1805f111305a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731965100,
      "headline": "Top Analyst Reports for Thermo Fisher, NextEra Energy & Lowe's",
      "id": 131461287,
      "image": "https://media.zenfs.com/en/zacks.com/f151141816757b508129c9e676699d7a",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), NextEra Energy, Inc. (NEE) and Lowe's Companies, Inc. (LOW).",
      "url": "https://finnhub.io/api/news?id=c04205ec1ad75b076f0db65053f4ac6c5cb57ad200088e3c5ba1805f111305a4"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria",
    "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.",
    "url": "https://finnhub.io/api/news?id=af5ff7d9becb927e0a2cd500965c57dcbf904c41a25b13772838a5f7fe0f0182",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731960000,
      "headline": "FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria",
      "id": 131461790,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.",
      "url": "https://finnhub.io/api/news?id=af5ff7d9becb927e0a2cd500965c57dcbf904c41a25b13772838a5f7fe0f0182"
    }
  },
  {
    "ts": null,
    "headline": "Buy 5 U.S. Bigwigs on the Dip for Sparkling Returns in the Short Term",
    "summary": "Five stocks currently available at attractive valuations after sizeable corrections in prices are: PFE, NEM, UBER, ADBE, QCOM.",
    "url": "https://finnhub.io/api/news?id=8bf73620bef167a91e4240275883cad06022cbfd1d2ed1da9e0a2bfc88b3a291",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731956400,
      "headline": "Buy 5 U.S. Bigwigs on the Dip for Sparkling Returns in the Short Term",
      "id": 131460935,
      "image": "https://media.zenfs.com/en/zacks.com/f8e8dd74fec7b16eb85235be391efa80",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Five stocks currently available at attractive valuations after sizeable corrections in prices are: PFE, NEM, UBER, ADBE, QCOM.",
      "url": "https://finnhub.io/api/news?id=8bf73620bef167a91e4240275883cad06022cbfd1d2ed1da9e0a2bfc88b3a291"
    }
  },
  {
    "ts": null,
    "headline": "How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health",
    "summary": "Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.",
    "url": "https://finnhub.io/api/news?id=851cf6b4c5d4a0866123957a35947294e4255cb32265a9dc3c0f0a274885791b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731954468,
      "headline": "How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health",
      "id": 131459215,
      "image": "https://s.yimg.com/ny/api/res/1.2/1DWnyssLRzOazAJTQv5_Dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDI-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/693db1d0-a5d6-11ef-bdb5-d669618dab8f",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks could be impacted, as well as which policies are in line for disruption.",
      "url": "https://finnhub.io/api/news?id=851cf6b4c5d4a0866123957a35947294e4255cb32265a9dc3c0f0a274885791b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock rises Monday, still underperforms market",
    "summary": "Pfizer Inc. stock rises Monday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=0648d8e08f9bb254c2c521f2fc02de48d75005f8b9b87c55679da37d40a17dcf",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731948000,
      "headline": "Pfizer Inc. stock rises Monday, still underperforms market",
      "id": 131475286,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock rises Monday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=0648d8e08f9bb254c2c521f2fc02de48d75005f8b9b87c55679da37d40a17dcf"
    }
  },
  {
    "ts": null,
    "headline": "Eyenovia Stock Tumbles on Termination of Phase III Myopia Study",
    "summary": "EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.",
    "url": "https://finnhub.io/api/news?id=c44e797f41fd091e9fdfe40a8810a4c08461a9fecddb07f70211ac33d3308c4f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731941340,
      "headline": "Eyenovia Stock Tumbles on Termination of Phase III Myopia Study",
      "id": 131458943,
      "image": "https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.",
      "url": "https://finnhub.io/api/news?id=c44e797f41fd091e9fdfe40a8810a4c08461a9fecddb07f70211ac33d3308c4f"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) the Best Immunotherapy Stock to Buy Now?",
    "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]",
    "url": "https://finnhub.io/api/news?id=52a8a2f450c1e7e239baa7880ba029188a6b79f090914341e4cfa57d24d9bb36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731941187,
      "headline": "Is Pfizer Inc. (PFE) the Best Immunotherapy Stock to Buy Now?",
      "id": 131459351,
      "image": "https://s.yimg.com/ny/api/res/1.2/EpAz_Vcy0hmyqhi5PSK_ZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]",
      "url": "https://finnhub.io/api/news?id=52a8a2f450c1e7e239baa7880ba029188a6b79f090914341e4cfa57d24d9bb36"
    }
  },
  {
    "ts": null,
    "headline": "ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study",
    "summary": "Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.",
    "url": "https://finnhub.io/api/news?id=b1585dce9dee28252d8b7d7d09505e0c00b9092cb71e7cd3f6b199531cf1c372",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731939960,
      "headline": "ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study",
      "id": 131459352,
      "image": "https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.",
      "url": "https://finnhub.io/api/news?id=b1585dce9dee28252d8b7d7d09505e0c00b9092cb71e7cd3f6b199531cf1c372"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Yield Dividend Stocks I Can't Stop Buying",
    "summary": "High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts.  Here's why these two high-yield dividend stocks deserve a closer look from income and value investors with a long-term outlook.  Pfizer (NYSE: PFE) ranks among healthcare's most reliable dividend payers, but recent struggles have pushed its stock down 13.8% this year.",
    "url": "https://finnhub.io/api/news?id=dd65a15c38dded8dfe272ce0eecbd4bf127d23450b4ce10f0fab8551b5eedcef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731930300,
      "headline": "2 High-Yield Dividend Stocks I Can't Stop Buying",
      "id": 131442494,
      "image": "https://g.foolcdn.com/editorial/images/798122/dividends-alternative.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts.  Here's why these two high-yield dividend stocks deserve a closer look from income and value investors with a long-term outlook.  Pfizer (NYSE: PFE) ranks among healthcare's most reliable dividend payers, but recent struggles have pushed its stock down 13.8% this year.",
      "url": "https://finnhub.io/api/news?id=dd65a15c38dded8dfe272ce0eecbd4bf127d23450b4ce10f0fab8551b5eedcef"
    }
  },
  {
    "ts": null,
    "headline": "FDA endorses speedy approval path for Regenxbio Duchenne gene therapy",
    "summary": "The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne gene therapies despite questions about their effectiveness.",
    "url": "https://finnhub.io/api/news?id=356b9f8d0af4c834d7e5999de11ec4e9a21fadb9d2e80c2946402191756a904e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731925380,
      "headline": "FDA endorses speedy approval path for Regenxbio Duchenne gene therapy",
      "id": 131459356,
      "image": "https://imgproxy.divecdn.com/U1QklxNetktAtJnLuPEw9_kaLqSq4r2HK2Evd5N1DsI/g:nowe:327:163/c:3508:1982/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTEwODY2NjkzNDIuanBn.webp",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The agency's openness to a targeted pivotal study shows it’s still willing to consider accelerated clearance for Duchenne gene therapies despite questions about their effectiveness.",
      "url": "https://finnhub.io/api/news?id=356b9f8d0af4c834d7e5999de11ec4e9a21fadb9d2e80c2946402191756a904e"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
    "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
    "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731903372,
      "headline": "Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy",
      "id": 131438224,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/601800909/image_601800909.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.",
      "url": "https://finnhub.io/api/news?id=b02e8a4d54768a2158d8e4696333123f7e491d50d8bf941ea6c0fab1b2b86d91"
    }
  }
]